All In MedTech

FDA Clearance Tracker · P990081-S059

PATHWAY anti- HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Dec 15, 2025 (this decision)Source: openFDAMethods & limitations

PMA supplement

The decision

FDA number
P990081-S059
Device name
PATHWAY anti- HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody
Applicant location
Tucson, AZ
Received
Aug 15, 2025
Decided
Dec 15, 2025
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P990081

Device type

Device class
Class III

Every decision under product code MVC

FDA's approval statement

As written in FDA's record.

This 180-day supplement is to expand labeling of the PATHWAY anti-HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody assay for use as a companion diagnostic to identify patients with HER2-positive, advanced or metastatic breast cancer who may be eligible for treatment with ENHERTU (fam-trastuzumab deruxtecan-nxki) in combination with PERJETA (pertuzumab) as first-line treatment.

Source documents

Other decisions for Ventana Medical Systems, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.